Sobi Advances Growth Strategy With Gamifant Launch In Early 2019 For Primary HLH
Executive Summary
The interferon gamma blocker is the first new therapy for HLH in 24 years. FDA approval came about four months after Sobi acquired global rights from NovImmune in a deal meant to improve the company's growth prospects.
You may also be interested in...
Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets
Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.
Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion
Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.